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Chronic wounds represent a major clinical problem
with significant morbidity and healthcare expendit-
ures, but no effective therapies. Topical platelet-
derived growth factor-BB trials have required large
and repeated doses to achieve only a modest effect.
We examined the ability of an adenovirus containing
the platelet-derived growth factor-B transgene to
improve the rate of wound healing through induction
of platelet-derived growth factor-B overexpression in
cells participating in the wound healing response. We
treated excisional wounds in the ischemic rabbit ear,
which have a 60% delay in healing, with vehicle,
106, or 108 plaque-forming units of an adenovirus
containing the platelet-derived growth factor-B per
wound (n J 19). At 7 d this resulted in a decrease in
the epithelial gap from 3.4 K 1 mm (mean K SD) in
vehicle-treated wounds to 1.9 K 1.8 mm (mean K SD,
p < 0.05) when treated with 106 plaque-forming units of
an adenovirus containing the platelet-derived growth
factor-B, and 0.7 K 1.1 mm (mean K SD, p < 0.001)
when treated with 108 plaque-forming units of an
adenovirus containing the platelet-derived growth fac-
Chronic nonhealing wounds, including ischemiculcers, decubitus ulcers, and diabetic foot ulcers canresult in prolonged hospitalization and lost time fromwork for as many as 5 million patients in the USAand an estimated healthcare expense of as much as
11 billion dollars a year worldwide (Mastov, 1994). If complications
from other causes of impaired wound healing, including the
use of corticosteroids, chemotherapy, radiation therapy, or severe
malnutrition, are considered, the scope of this problem takes on
even greater proportions. To date, effective therapies for both
chronic nonhealing wounds and impaired wound healing have
been lacking.
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tor-B. Ischemic excisional wounds treated with 108
plaque-forming units of an adenovirus containing the
platelet-derived growth factor-B even healed more
rapidly than non-ischemic excisional wounds treated
with vehicle (p < 0.05). In contrast, 5 mg of platelet-
derived growth factor-BB protein (n J 2) resulted in
only modest granulation tissue at the margin, but no
significant differences in epithelial gap (3 K 0.6 mm,
mean K SD). Plaque-forming units (106 or 108) of an
adenovirus containing the b-galactosidase transgene
(n J 4) impaired wound re-epithelialization with an
epithelial gap of 5.11 K 0.69 mm, mean K SD,
p < 0.004, and 3.8 K 0.57 mm, mean K SD, p < 0.07,
respectively. Adenoviral-mediated gene transfer of
platelet-derived growth factor-B overcame the isch-
emic defect in wound healing and offers promise in
the treatment of chronic nonhealing wounds. The
vulnerary effects of platelet-derived growth factor-B
overexpression were sufficient to overcome the adverse
effects of the adenovirus or transgene on wound
healing. Key words: adenovirus/gene therapy/skin. J Invest
Dermatol 113:375–383, 1999
Whereas the etiology of wound healing impairment in chronic
wounds appears to be multifactorial, growth factor deficiencies
have been shown to be important. Chronic dermal ulcers have
been shown to be deficient in platelet derived growth factor
(PDGF) and in patients with chronic ulcers that eventually heal,
increased serum levels of PDGF have been detected (Chleboun
et al 1995; Pierce et al, 1995).
PDGF plays an important part in each stage of wound healing
beginning with its release from the alpha granules of platelets during
formation of the wound hemostatic plug (Kaplan et al, 1979).
Although the predominant PDGF released is the AB heterodimer,
the most potent form of PDGF by in vitro testing is the BB
homodimer (Seppa et al, 1982). PDGF has been shown to stimulate
fibroblast proliferation and chemotaxis, as well as the synthesis of
extracellular matrix (Kaplan et al, 1979; Seppa et al, 1982; Heldin
et al 1989). PDGF is also secreted by fibroblasts, activated macro-
phages, and endothelial cells (Shimokado et al, 1985; Harlan et al,
1986; Paulsson et al, 1987). In addition to autocrine and paracrine
stimulation of its own production (Paulsson et al, 1987), PDGF
stimulates production of other growth factors and cytokines import-
ant in wound healing, such as transforming growth factor-β (Pierce
et al, 1989), vascular endothelial growth factor (Sato et al, 1993),
keratinocyte growth factor (Li and Tseng, 1997), and monocyte
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chemotactic protein-1 (Poon et al, 1996). The central role of PDGF
in all phases of wound healing has resulted in both experimental
and clinical interest in exogenous PDGF protein application to
chronic nonhealing wounds.
Despite data demonstrating a favorable effect of topical PDGF-
BB on wound healing, large and repeated doses were required for
even a modest clinical effect (Mustoe et al, 1991, 1994; Pierce et al,
1991; Wieman et al, 1998). Although disappointing these clinical
studies demonstrate that PDGF-BB can favorably affect wound
healing, but a more efficient means of delivery of PDGF-BB
directly to cells participating in the wound healing response is
needed. Gene transfer is an appealing strategy that may allow direct
delivery of growth factor to the wound through the induction of
growth factor gene expression in cells participating in the wound
healing response.
We hypothesized that a replication deficient adenovirus could
achieve efficient delivery of the PDGF-B transgene directly to cells
participating in the wound healing response, and that the induction
of PDGF-B overexpression could overcome an ischemic wound
healing defect. The ischemic rabbit ear model of impaired excisional
wound healing (Ahn and Mustoe, 1990) was used to test the effect
of adenoviral-mediated overexpression of the PDGF-B transgene on
the rate of re-epithelialization, wound closure, and the production of
granulation tissue and extracellular matrix.
MATERIALS AND METHODS
Animal model An ischemic ear was created in one ear of 10–12 wk
old female New Zealand white rabbits (Ace Animals, Boyletown, PA) as
previously described (Ahn and Mustoe, 1990). One day following creation
of the ischemic ear a sterile surgical punch biopsy instrument (Miltex
Instrument, Lake Success, NY) was used to create two 6 mm wounds on
the ventral surface of both the ischemic ear and the contralateral non-
ischemic ear.
Adenoviral construction The PstI/EcoRI DNA fragment containing
the open-reading frame derived from the full length human PDGF-B
cDNA (provided by B. Westermark, University of Uppsala, Sweden), was
cloned into the PstI/EcoRI restriction site of pSL301 (Invitrogen, Carlsbad,
CA). The resulting plasmid was cut with NotI (Promega, Madison, WI)
and the fragment subcloned into the adenoviral vector pADCMV-Link.1
(Davis and Wilson, 1994). The resulting plasmid was cut with EcoRI
(Promega) to determine the orientation of the PDGF-B gene.
The pADCMV plasmid containing the sense oriented PDGF-B gene
was cut with NheI (Promega) and calcium-precipitated together with ClaI-
digested adenoviral DNA (dL7001 Ad5) lacking the E1 and E3 genes
(Ranheim et al, 1993). DNA precipitates were incubated with human
embryonic 293 cells containing the E1 genes of Ad5 for 5 h. Following
which the 293 cells were subjected to 10% glycerol shock for 2 min in
serum-free Dulbecco’s modified Eagle’s media and then grown overnight
in Dulbecco’s modified Eagle’s media with 10% fetal bovine serum. Eagle
media (Gibco/BRL, Gaithersburg, MD) with 2% fetal bovine serum, 0.8%
agar (Gibco), and 0.5 mM MgCl2 was then placed over the cells. Fresh
overlay was added every 4 d until the appearance of individual plaques.
Plaques were expanded in 293 cells grown in Dulbecco’s modified Eagle’s
media containing 10% fetal bovine serum until cytopathic effects were
observed. Cells were then harvested and adenoviral DNA isolated as
previously described (Hirt, 1967). Adenoviral DNA was verified to contain
the human PDGF-B gene by southern blot analysis (Sambrook et al 1989),
using the PstI/EcoRI fragment of the PDGF-B gene as a probe. Rabbit
fibroblasts infected with the recombinant adenovirus containing the PDGF-
B transgene (Ad-PDGF-B) were verified to produce human PDGF-BB
protein by western blot analysis as previously described (Sambrook et al
1989). In addition, biologic activity of the transgene product was verified
by the ability to stimulate proliferation of rabbit fibroblasts.
Adenovirus containing the β-galactosidase transgene (Ad-LacZ) was
obtained from the Institute for Human Gene Therapy (University of
Pennsylvania, Philadelphia, PA), and expanded to obtain a large preparation
of Ad-LacZ. Ad-LacZ and Ad-PDGF-B were then purified by cesium
chloride centrifugation and then desalted using a DG-10 column (Bio-
Rad Laboratories, Hercules, CA). The particle number for Ad-PDGF-B
and Ad-LacZ were determined by absorption at A260 using a DU-640
spectrophotometer (Beckman Instruments, Fullerton, CA) and the final
plaque-forming units (PFU) determined by titration on 293 cells under an
agar overlay (Graham and Eb, 1973). The final particle/PFU ration was
25 : 1 for the Ad-LacZ vector and 1000:1 for the Ad-PDGF-B vector.
Replication competent adenovirus was excluded from both adenoviral
constructs as previously described (Davis and Wilson, 1994). In brief, the
human lung carcinoma cell line A549 (American Type Culture Collection,
Rockville, MD), a cell line known to be very susceptible to adenoviral
infection, was incubated with either the adenoviral construct alone,
replication competent adenovirus alone, or a combination of the two.
Cells were observed twice a week for 2 wk for cytopathic effects. At 14 d
the cells were scraped and a cell lysate formed with multiple freeze–thaw
cycles. This lysate was then used to infect new A549 cells. The cells were
incubated for 1 wk and observed for cytopathic effects. The cells were
again lysed and the cycle repeated for 1 more week. Replication competent
adenovirus was considered to be excluded if no cytopathic effects were noted
during these 28 d of incubation. The replication competent adenovirus assay
was sensitive to detect one replication competent adenovirus per 1011
adenoviral particles.
Administration of adenovirus After the creation of the ischemic or
non-ischemic wounds, 106 or 108 PFU of Ad-PDGF-B or Ad-LacZ in
50 µl of vehicle (20 mM HEPES/150 mM NaCl, pH 7.8, containing 10%
glycerol), or vehicle, was injected intradermally around the wound using
a Hamilton 50 µl syringe and 30 gauge needle (Hamilton Company, Reno,
NV). Injection of 5 µg per wound of recombinant PDGF-BB (Sigma, St
Louis, MO) was also performed for comparison. Following injection the
wounds were dressed with Tegaderm.
Tissue processing At 3, 7, and 16 d after wounding, the wounds were
harvested and either fixed overnight in 10% neutral buffered formalin at
4°C and paraffin embedded or cryopreserved in 20% sucrose overnight at
4°C followed by embedding in OCT media (Miles, Elkhart, IN) as
previously described (Culling, 1974). Full thickness skin was excised in a
8 mm radius centered on the site of the original wound, snap frozen in
liquid nitrogen for later isolation of total RNA or DNA.
Histology Serial 5 µm sections were obtained from the paraffin embed-
ded wounds using a 30/50 microtome (Leica, Heidelberg, Germany) and
stained with hematoxylin and eosin as previously described (Culling, 1974).
On microscopic examination the epithelial gap, defined as the distance
between encroaching epidermal elements, was measured using a stage
micrometer (Leica). Granulation tissue volume was determined in square
millimeters using Image-Pro Plus 3.0 software (Media Cybernetics, L.p.,
Silver Spring, MD). The boundaries of the granulation tissue bed were
defined laterally by the transition zone from normal epidermis to hyper-
trophic epidermis, inferiorly by the ear cartilage, and superiorly by epithelial
basement membrane or the open wound surface.
Immunohistochemistry Rehydrated, serial paraffin sections (5 µm)
were immersed in Tissue Unmasking Fluid (Signet Laboratories, Dedham,
MA) to reactivate hidden or masked epitopes and then placed in a
microwave (Ted Pella, Redding, CA) for 5 min on high power. Samples
were blocked with nonimmune goat serum followed by incubation with
a polyclonal goat anti-human PDGF-B (R&D Systems, Minneapolis, MN)
at 4°C. The slides were washed with phosphate-buffered saline (PBS) and
endogenous peroxidase activity blocked with methanol containing 0.3%
hydrogen peroxide. Slides were rinsed with PBS and then incubated with
biotinylated horse antigoat (Vector Labs, Burlingame, CA). The slides were
washed with PBS and avidin–biotin complex (Vector Labs) added. The
slides were rinsed in PBS, developed with chromagen 3,39-diaminobenzid-
ine (Sigma) and lightly stained with hematoxylin.
In situ hybridization Paraffin sections (4 µm) were deparaffinated and
rehydrated through a graded alcohol series to deionized water and allowed
to air dry completely. Slides were then treated with proteinase K (10 µg
per ml, Boehringer Mannheim), washed in PBS, and postfixed in 4%
paraformaldehyde. Sections were covered with hybridization solution
containing 50 ng biotinylated DNA probe, 50% foramide, 20% dextran
sulfate, and 1 3 sodium citrate/chloride buffer. Slides were heated for
10 min at 95°C and hybridized overnight in a humid chamber at 37°C.
Slides were washes four times with 1 3 sodium citrate/chloride buffer for
15 min at 50°C. The slides were then blocked with 0.1 M Tris-buffered
saline (pH 7.4) containing 0.1% bovine serum albumin (Sigma) and 1 mM
levamisole (Sigma). Streptavidin–alkaline phosphatase conjugate (1:75 dilu-
tion, Amersham, Arlington Heights, IL) was added to the slides for 30 min
at 37°C. Slides were washed with 0.1 M Tris-buffered saline for 20 min
at room temperature. Bound streptavidin–alkaline phosphatase conjugate
was detected by incubating the slides at 37°C in alkaline phosphatase
substrate solution (Gibco/BRL) for 2 h. Slides were counterstained with
nuclear fast red 1% (Sigma).
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RNA isolation and reverse transcription Total cellular RNA from
the wounds was isolated using Tri Reagent (Molecular Resource Center,
Cincinnati, OH). as previously described (Chomczynski and Sacchi, 1987).
First-strand cDNA was prepared from 1 µg total cellular RNA, as previously
described (Sambrook et al 1989). In brief, 1 µg of total cellular RNA in
9 µl total volume was added to each 0.65 ml microcentrifuge tube and
placed on ice. A master mix was prepared and added on ice such that the
final concentration of reagents for each sample was 200 U Moloney Murine
Leukemia Virus Reverse Transcriptase (Gibco/BRL), 40 U RNAsin
(Promega), 100 pmol of random hexamers (Boehringer Mannheim), 1 mM
dithiothreitol, 500 µM deoxytriphosphates (Gibco/BRL), 50 mM KCl,
10 mM Tris–Cl (pH 8.3 at 22°C), 2.5 mM MgCl2, and 0.01% gelatin.
After 1 h at 37°C the reverse transcriptase reaction was heat inactivated
by incubation for 5 min at 94°C.
DNA isolation Total DNA from the wounds was isolated using DNAzol
(Molecular Resource Center). In brief, approximately 100 mg of tissue
was homogenized in 1 ml of DNAzol. The DNA was precipitated with
0.5 ml of 100% ethanol. The DNA precipitate was pelleted by centrifugation
and then washed twice with 95% ethanol. The DNA pellet was then
dissolved in sterile water.
Polymerase chain reaction (PCR) analysis Specific primers for human
PDGF-B and rabbit β-actin were selected based on the published human
PDGF-B cDNA (Collins et al, 1985) and rabbit β-actin cDNA sequences
(Sakai et al 1995). The human PDGF-B primer pair used was upstream
primer 59-TGGGCGCTCTTCCTGTCTCTC and downstream primer
59-CTCGGCCCCATCTTCCTCTCC resulting in a 165 base pair prod-
uct. The rabbit β-actin primer pair used was upstream primer 59-
TGGGCAGAAGGACTCGTA and downstream primer 59-CGCAGCT-
CGTTGTAGAAG resulting in a 144 base pair product. PCR was
performed on aliquots of the cDNA or total DNA prepared above as
previously described (Gilliland et al, 1990). In brief, either 5 µl of the
reverse transcriptase reaction or 0.5 µg total DNA was added to each
0.65 ml microcentrifuge tube and placed on ice. A master mix was prepared
and added on ice such that the final concentration of reagents for each
sample was 2.5 U Amplitaq Gold DNA polymerase (Perkin Elmer,
Norwalk, CT), 200 µM deoxytriphosphates (dNTP, Pharmacia, Piscataway,
NJ), 50 mM KCl, 10 mM Tris–Cl (pH 8.3 at 22°C), 1.5 mM MgCl2,
0.01% gelatin, and 1 µM upstream and downstream primers. The samples
were kept on ice until the thermocycler block (Hybaid Limited, Manchester,
U.K.) was at 94°C, when the samples were immediately placed into the
block for 9 min. Samples were amplified using 30 cycles for cDNA and
45 cycles for DNA of 30 s at 94°C followed by 30 s annealing at 58°C
for PDGF-B or 54°C for β-actin in separate tubes followed by 1 minute
of extension at 72°C. Upon completing the final cycle, samples were
incubated for 5 min at 72°C. The PDGF-B primers were shown to be
specific for human PDGF-B and not to amplify rabbit PDGF-B (Data
not shown).
PCR was used to generate a biotinylated probe for in situ hybridization
using the PstI/EcoRI fragment of the PDGF-B gene as a template. The
PCR primers and conditions were the same as described for PDGF-B with
the exception of the dNTP concentrations, which were 80 µM for dATP,
dGTP, and dCTP with 52 µM for dTTP and 28 µM for biotin-16–29-
deoxyuridine-59-triphosphate (dUTP, Boehringer Mannheim). The 165
base pair PCR product, corresponding to base pairs 136–288 of the coding
sequence of the PDGF-B gene, was separated from unincorporated
nucleotides using a G-50 Sephadex spin column (Boehringer Mannheim).
Statistical analysis Differences in the epithelial gap between the ischemic
and non-ischemic wounds were analyzed by the nonpaired t test. Differences
in adenoviral and vehicle treated groups were assessed by analysis of
variance and the nonpaired t test with the Bonferroni correction.
RESULTS
Effect of ischemia on wound histology and re-
epithelialization In order to confirm wound healing impairment
in our model, wound healing was examined histologically and
quantitated by measuring the epithelial gap in ischemic and non-
ischemic rabbit ears. At 7 d ischemic wounds (n 5 14) had minimal
re-epithelialization and absent granulation tissue in the wound bed
(Fig 1A). In contrast, at 7 d non-ischemic wounds (n 5 16) have
re-epithelialized 60% of the original wound defect and have a
modest amount of granulation tissue (Fig 1B). Ischemic wounds
at 7 d had an epithelial gap of 3.4 6 1 mm vs 2.3 6 1.4 mm
(mean 6 SD) in the non-ischemic wounds (p , 0.006, Fig 2).
By 16 d the ischemic wounds (n 5 4) still have not completely
re-epithelialized with an epithelial gap of 1.15 6 0.35 mm, but do
show a moderate amount of granulation tissue (Fig 1C). In contrast,
at 16 d the non-ischemic wounds (n 5 4) have all completely re-
epithelialized and show maturation of granulation tissue (Fig 1D).
Effect of Ad-PDGF-B on wound histology In order to assess
the effect of Ad-PDGF-B on wound healing, all wounds were
examined histologically and wound healing quantitated by measur-
ing the epithelial gap and granulation tissue volume. Treatment of
ischemic wounds with a single intradermal injection of 106 PFU
of Ad-PDGF-B per wound (n 5 10) resulted in correction of the
wound healing impairment at 7 d, with formation of a large amount
of granulation tissue and partial re-epithelialization (Fig 3B),
indicated by a decrease in the epithelial gap to 1.9 6 1.8 mm
(p , 0.05 versus vehicle control, Fig 4A). Treatment of ischemic
wounds with 108 PFU of Ad-PDGF-B per wound (n 5 9) resulted
in an even more dramatic improvement in wound healing at 7 d,
with a large amount of granulation tissue and complete (n 5 6) or
near complete (n 5 3) re-epithelialization (Fig 3C), as indicated
by a decrease in the epithelial gap to 0.7 6 1.1 mm (p , 0.001
versus vehicle control, Fig 4A). By 16 d after wounding, the
ischemic wounds treated with 108 PFU Ad-PDGF-B demonstrated
resolution of the exuberant granulation tissue response (Fig 3D)
with an appearance similar to the non-ischemic vehicle-treated
wounds (Fig 3E). Treatment of non-ischemic wounds with 106
PFU of Ad-PDGF-B per wound (n 5 9) resulted in a slight
improvement in wound re-epithelialization at 7 d as indicated by
a decrease in the epithelial gap to 1.3 6 1.5 mm vs 2.3 6 1.4 mm
in the vehicle-treated non-ischemic wounds (Fig 4B). Treatment
of non-ischemic wounds with 108 PFU of Ad-PDGF-B per wound
(n 5 9) resulted an epithelial gap of 2.8 6 1.4 mm. Treatment of
non-ischemic wounds with 106 or 108 PFU of Ad-PDGF-B,
however, did not significantly improve wound re-epithelialization.
By 16 d all ischemic and non-ischemic wounds treated with Ad-
PDGF-B had completely re-epithelialized. A single intradermal
administration of 5 µg recombinant human PDGF-BB protein into
ischemic wounds (n 5 2) only resulted in a slight increase in
granulation tissue at the wound margin at 7 d, but no differences
in granulation tissue in the wound base (Fig 3F) or in re-
epithelialization (Fig 4A), with an epithelial gap of 3 6 0.6 mm. No
β-galactosidase transgene expression was detected histochemically in
ischemic wounds treated with 106 PFU of Ad-LacZ (n 5 4,
Fig 3G). Treatment of ischemic wounds with the higher dose of
108 PFU Ad-LacZ (n 5 4) resulted in β-galactosidase transgene
expression at 7 d, evidenced by the blue cells at the wound margin.
Treatment with either 106 or 108 PFU of Ad-LacZ did not improve
wound granulation tissue formation and actually impaired wound
re-epithelialization with increase in epithelial gap to 5.11 6 0.69 mm
(Fig 4C, p , 0.004 versus vehicle) and 3.8 6 0.57 mm, respectively
(p , 0.07 versus vehicle). At 7 d ischemic wounds treated with
108 PFU of Ad-PDGF-B had a significantly higher granulation
tissue volume of 7.0 6 1.8 mm2 (p , 0.000001, Fig 4D) compared
with the ischemic wounds treated with vehicle (2.1 6 0.8 mm2).
Detection of human PDGF-BB protein by immunohisto-
chemistry In order to confirm PDGF-BB protein production
following gene transfer, wounds were analyzed by immunohisto-
chemistry using an antibody specific for human PDGF-BB. Ischemic
wounds treated with vehicle demonstrated minimal immunohisto-
chemical staining for human PDGF-BB protein at 3 d (Fig 5A).
In contrast, there was extensive and specific immunostaining for
human PDGF-BB protein in the ischemic wounds treated with
108 PFU Ad-PDGF-B (Fig 5B). This immunostaining localized
to fibroblasts and endothelial cells in the wound margin participating
in the wound healing response.
Localization of Ad-PDGF-B infected cells by in situ
hybridization In order to confirm the presence of vector derived
human DNA in cells participating in wound healing, in situ
hybridization for human PDGF-B was performed on ischemic
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Figure 1. Histologic analysis of vehicle-treated wounds. Six millimeter excisional wounds in ischemic and non-ischemic rabbit ears were treated
with an intradermal, circumferential injection of the vehicle used to resuspend the adenovirus. The wounds were then harvested at 7 and 16 d.
Hematoxylin and eosin staining of the vehicle-treated ischemic wounds (A) and non-ischemic wounds (B) at 7 d is shown. The edge of the encroaching
epithelium is indicated by the arrows. Also shown is the hematoxylin and eosin staining of vehicle-treated ischemic wounds (C) and non-ischemic wounds
(D) at 16 d. Scale bar: 1 mm.
Figure 2. Measurements of epithelial gap in vehicle-treated wounds.
Wounds were harvested 7 d after wounding from 6 mm ischemic and
non-ischemic rabbit ear wounds treated with an intradermal, circumferential
injection of vehicle. Tissue sections from the wounds were hematoxylin
and eosin stained and the epithelial gap measured as the distance between
the epithelial margins measured using a stage micrometer. Vehicle treated
ischemic rabbit ears (n 5 14) are demonstrated by the open bar and non-
ischemic wounds (n 5 16) by the solid bar.
wounds 3 d after wounding. Ischemic wounds treated with vehicle
demonstrated no in situ hybridization signal (Fig 6A). In contrast,
ischemic wounds treated with 108 PFU Ad-PDGF-B demonstrated
dense in situ hybridization signal (Fig 6B). Cells that had positive
in situ hybridization appeared to be primarily fibroblasts at the
wound margin which were participating in the wound healing
response.
Duration of transgene expression by reverse transcriptase–
PCR In order to assess the duration of transgene expression in
the wounds, reverse transcriptase–PCR analysis for human-specific
PDGF-B was performed and demonstrated significant amounts of
human PDGF-B mRNA at 3 d in both the ischemic and non-
ischemic wounds treated with 108 PFU Ad-PDGF-B (Fig 7A).
By 7 d, very little human PDGF-B mRNA was detected in both
ischemic and non-ischemic wounds receiving 106 or 108 PFU Ad-
PDGF-B, consistent with clearance of transgene expression from
the wounds. No significant difference was noted in rabbit specific
β-actin controls.
Persistence of adenoviral DNA by PCR In order to asses the
duration of adenoviral DNA in the wounds, PCR was performed
for the human specific PDGF-B transgene. At 14 d no adenoviral
DNA was detected in ischemic wounds treated with 106 or 108
PFU Ad-PDGF-B, despite using 45 PCR cycles (Fig 7B). With
45 cycles, adenoviral DNA was detected in non-ischemic wounds
treated with 106 or 108 PFU Ad-PDGF-B. There was no difference
in β-actin controls.
DISCUSSION
Gene therapy using an adenoviral vector containing the PDGF-B
transgene overcame the significant deficit in wound healing seen
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Figure 3. Histologic analysis of wounds treated with Ad-PDGF-B, Ad-LacZ, or PDGF-BB protein. The 6 mm excisional wounds in the
ischemic rabbit ear were treated with an intradermal, circumferential injection of either vehicle, 106 or 108 PFU of either Ad-PDGF-B or Ad-LacZ, or
5 µg of recombinant PDGF-BB protein. The wounds were harvested 7 or 16 d after wounding. Hematoxylin and eosin staining of vehicle treated
ischemic excisional wounds demonstrates the epithelial defect (A), indicated by the arrows, and the absence of granulation tissue in the wound base.
Hematoxylin and eosin staining of ischemic wounds treated with 106 PFU of Ad-PDGF-B per wound (n 5 10) is shown in (B). The improvement in
wound healing, complete re-epithelialization, and exuberant granulation tissue response of ischemic wounds treated with 108 PFU of Ad-PDGF-B per
ischemic wound (n 5 9) is shown in (C). Part (D) demonstrates the complete re-epithelialization and maturation of granulation tissue seen 16 d after
treatment of ischemic wounds treated with 108 PFU Ad-PDGF-B. An hematoxylin and eosin stain of a non-ischemic vehicle-treated wound at 16 d is
shown for comparison (E). Part (F) demonstrates the minimal granulation tissue at the wound margin, but lack of improvement in granulation tissue in
the wound base or in re-epithelialization seen in ischemic wounds treated with 5 µg recombinant human-PDGF-BB. β-galactosidase staining of ischemic
wounds treated with 106 PFU of Ad-LacZ at 7 d demonstrates no transgene expression seen in these wounds (G). β-galactosidase staining of ischemic
wounds treated with 108 PFU of Ad-LacZ demonstrates β-galactosidase transgene expression, as evidenced by blue cells in the wound margin (H). The
edge of epithelium is indicated by the arrows. Scale bar: (A–E) 1 mm; (F–H) 200 µm.
in ischemic rabbit ear excisional wounds. A single administration
of Ad-PDGF-B resulted in correction of the ischemic impairment
in wound re-epithelialization not only compared with vehicle, Ad-
LacZ, or recombinant human PDGF-BB-treated ischemic wounds,
but even compared with non-ischemic control wounds. Treatment
of ischemic wounds with Ad-PDGF-B also significantly increased
granulation tissue formation and also appears to have increased
extracellular matrix production, and angiogenesis compared with
vehicle, Ad-LacZ, or recombinant human PDGF-BB-treated
wounds. This ischemic rabbit ear model poses a formidable challenge
to wound healing, with a marked delay in wound closure (Ahn
and Mustoe, 1990) and minimal contribution of wound contraction
to the healing response. The removal of the perichondrium in the
base of the wounds requires the wound to heal by the formation
of granulation tissue and re-epithelialization from the periphery
(Chen et al, 1992). Acceleration of wound closure observed in
response to Ad-PDGF can only be achieved by increasing both
the rate of granulation tissue production at the wound margin and
the rate of keratinocyte migration over the wound bed.
Despite an extensive literature on the use of exogenous PDGF-
BB protein in wound healing, results comparable with those
achieved with Ad-PDGF-B have not been observed (Mustoe et al,
1991, 1994; Pierce et al, 1991; Robson et al, 1992; Steed, 1995;
Wieman et al, 1997). In our experiments, granulation tissue and
re-epithelialization of wounds treated with PDGF-BB protein were
not significantly different from vehicle-treated wounds. Similarly,
previous reports of topical application of PDGF-BB protein in the
non-ischemic rabbit ear model resulted in only a modest increase
in granulation tissue (53%). In addition, in the non-ischemic
model limited improvement in wound closure was observed, with
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Figure 4. Measurements of epithelial gap in wounds treated with
Ad-PDGF-B, Ad-LacZ, or PDGF-B protein. Wounds were harvested
7 d after wounding from 6 mm ischemic rabbit ear wounds treated with
an intradermal, circumferential injection of vehicle, 106 or 108 PFU of
Ad-PDGF-B or Ad-LacZ, or 5 µg of recombinant PDGF-BB protein.
Tissue sections from the wounds were hematoxylin and eosin stained and
the epithelial gap measured as the distance between the epithelial margins
measured using a stage micrometer. (A) Ischemic wounds treated with
vehicle is shown by the open bar, 106 PFU of Ad-PDGF-B per wound
(n 5 10) is shown by the solid bar, and 108 PFU of Ad-PDGF-B per
wound (n 5 9) by the striped bar. (B) Non-ischemic wounds treated with
vehicle is shown by the open bar, 106 PFU of Ad-PDGF-B per wound
(n 5 9) is shown by the solid bar, and 108 PFU of Ad-PDGF-B per wound
(n 5 9) by the striped bar. (C) Treatment of ischemic wounds with vehicle
(open bar), 5 µg recombinant PDGF-BB protein (solid bar), 106 PFU of
Ad-LacZ (cross-hatched bar, n 5 7), or 108 PFU of Ad-LacZ (vertical striped
bar, n 5 4) is shown. (D) Granulation tissue volume was quantitated using
Image-Pro Plus 3.0 software in ischemic wounds treated with vehicle (open
bar) or 108 PFU of Ad-PDGF-B (solid bar).
Figure 5. Immunohistochemical analysis for PDGF-BB in wounds
treated with Ad-PDGF-B. Production of human PDGF-BB protein was
examined in wounds harvested 7 d after wounding from ischemic rabbit
ears treated with an intradermal, circumferential injection of either vehicle
or 108 PFU of Ad-PDGF-B by immunohistochemistry. Immunostaining
of an ischemic wound treated with either vehicle (A) or 108 PFU Ad-
PDGF-B (B) is shown. Scale bar: 25 µm.
complete closure of 56% of the PDGF-BB-treated wounds versus
25% complete closure of vehicle-treated wounds (Mustoe et al,
1991). In our study, even in the presence of ischemic wound
healing impairment, Ad-PDGF-B resulted in a 66% incidence of
complete wound closure. Ad-PDGF-B completely overcame the
ischemic wound healing deficit, as these ischemic wounds healed
even more rapidly than even non-ischemic wounds. Human clinical
trials involving the topical application of PDGF-BB protein to
diabetic and decubitus ulcers have thus far reported only modest
improvements in wound closure, despite large repetitive doses, and
a long duration of therapy (Pierce et al, 1991; Mustoe et al, 1994;
Wieman et al, 1997). Possible factors responsible for the limited
effect of exogenous PDGF-B protein include binding of growth
factor to macroglobulins, fibronectin, or proteoglycans in the
wound base rendering them biologically unavailable (Folanga and
Eaglstein, 1993; Whitelock et al, 1996), or increased degradation
of growth factor as a result of the elevated matrix metalloproteinases
in chronic wounds (Grinnell et al 1992).
The very modest improvement in wound healing observed with
PDGF-BB protein demonstrates that PDGF-BB can improve
chronic or impaired wound healing, but a better method of delivery
is needed. Gene transfer has previously been attempted in wound
healing. Application of plasmid DNA, or DNA particle bombard-
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Figure 6. In situ hybridization for PDGF-B gene
in wounds treated with Ad-PDGF-B. In situ
hybridization was performed for Ad-PDGF-B on
wounds harvested 3 d after wounding from ischemic
rabbit ears treated with an intradermal, circumferential
injection of either vehicle or 108 PFU of Ad-PDGF-
B. In situ hybridization of ischemic wounds treated
with either vehicle (A) or 108 PFU Ad-PDGF-B (B)
is shown. Scale bar: 50 µm.
Figure 7. Reverse transcriptase–PCR and PCR analysis for PDGF-
B mRNA and transgene DNA in wounds treated with Ad-PDGF-
B. (A) The amount and duration of human-specific PDGF-B mRNA
production in wounds harvested 3 and 7 d after wounding from ischemic
rabbit ears treated with an intradermal, circumferential injection of 108
PFU of Ad-PDGF-B using reverse transcriptase–PCR analysis is shown.
(B) The presence of adenoviral PDGF-B transgene DNA from ischemic
and non-ischemic wounds harvested 14 d after treatment with 106 or 108
PFU of Ad-PDGF-B is shown.
ment, has been used, but has had limited success (Chen and
Okayama, 1988; Andree et al, 1994; Krueger et al, 1994; Benn
et al, 1996). In order to improve efficiency of retroviral infection,
in vitro transfection of keratinocytes with retrovirus, followed by
incorporation into an acellular cadaveric dermis, and subsequent
transplantation, has been attempted (Eming et al, 1995, 1998). This
increased transfection efficiency to between 40% and 80%, much
lower than the 95% efficiency observed with adenovirus (Kozarsky
and Wilson, 1993), but also required cumbersome ex vivo transfec-
tion techniques. In addition, these ex vivo studies examined the
effect of recombinant growth factor production on graft survival
and did not examine the effects of growth factor on wound healing.
In each instance either low efficiency of gene transfer, limited
biologic effect of the transgene in wound healing, or cumbersome
techniques have been responsible for the limited effect of previous
gene therapy applications in wound healing. This experience
lead us to the alternative of adenoviral-mediated gene transfer.
Adenoviruses have been shown to be very efficient in gene transfer,
infecting skin cells at more than 95% efficiency in vitro (Kozarsky
and Wilson, 1993). Previously, an adenovirus has been used to
effect reporter gene transfer to the skin without adverse effects (Lu
et al, 1997), but this study did not examine the effect of adenoviral
infection on wound healing. In this current study, an adenovirus
containing the PDGF-B transgene, a growth factor with significant
biologic effect in wound healing, was used successfully in the
induction of PDGF-B gene overexpression, resulting in reversal
of the ischemic impairment in wound healing and rapid re-
epithelialization of the wound.
Adenovirus as a means of gene transfer has been reported in the
treatment of genetic diseases such as cystic fibrosis and hypercholes-
terolemia (Kozarsky et al 1993; Grubb et al, 1994). Low transduction
rates, short duration of adenoviral transgene expression, as well as
the need for re-administration, however, have limited the success
of adenovirus in gene therapy in these applications (Kozarsky and
Wilson, 1993). These limitations are due in part to immunologic
response to both the adenovirus as well as the transgene. In the
setting of wound healing, where correction of a genetic defect is
not the goal, however, the limited duration of transgene expression
may prove to be advantageous, with clearance of the adenovirus
and transgene by the time of wound closure. Unlike other potential
applications of adenoviral-mediated gene therapy, limited duration
of high-level transgene expression may be all that is necessary to
effect wound healing in chronic nonhealing wounds. In addition,
once skin integrity is re-established, the need for re-administration
is not needed. In cases where skin integrity has not been fully re-
established, re-administration may be necessary; however, the
duration of transgene may be affected by the immune response.
In contrast to the significant improvement in wound healing
achieved by Ad-PDGF-B in ischemic wounds, Ad-Lacz adversely
affected wound healing with a significant increase in the epithelial
gap compared with vehicle control. Previous work in our laboratory
studying gene therapy in a nonimpaired model of wound healing
demonstrated an acute inflammatory response to adenoviral admin-
istration, but no adverse effect on wound healing (Sylvester et al
382 LIECHTY ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
submitted). The adverse effect on wound healing seen with Ad-
LacZ in this model of impaired wound healing may be the result
of the inflammatory response to the adenovirus or the transgene
product in the wound. Alternatively, the negative effect may be
related to the properties of the ischemic rabbit ear model, where
an already impaired wound is unable to tolerate further inflammation
due to the adenoviral infection. A direct cytotoxic effect of the
adenovirus is unlikely with the recombinant adenovirus used in
these studies being free of cytolytic effects. This observation makes
the vulnerary effects of Ad-PDGF-B all the more impressive. Not
only was Ad-PDGF-B able to overcome the ischemic defect in
wound healing, but it was also able to overcome the potentially
negative effect of adenovirus on impaired wound healing. This
negative effect was overcome, however, with the selection of a
proper transgene with known biologic effects in wound healing
(Kaplan et al, 1979).
In the non-ischemic wounds there appeared to be improvement
in wound re-epithelialization in wounds treated with 106 PFU Ad-
PDGF-B, but no improvement in wounds treated with 108 PFU
Ad-PDGF-B. The lack of a statistically significant effect may be
due to the fact that these wounds are healing at near maximal
rate. To detect a small improvement in wound healing in these
nonimpaired wounds a larger sample size may be needed.
One potential concern of using adenovirus containing the human
PDGF-B transgene is its homology to the gene product of the
simian sarcoma virus (SSV p28v-sis), which also acts through the
PDGF receptor. The effect of the SSV p28v-sis gene product is
mediated through chronic activation of the PDGF pathway,
resulting in persistent cell proliferation and ultimately cell trans-
formation (Johnsson et al, 1986). The SSV p28v-sis is a retrovirus
that integrates into the host cell DNA, but is not immortalizing, with
SSV p28v-sis transformed cells living no longer than nontransformed
cells. In contrast, adenoviruses remain episomal and rarely integrate
into the human genome (Bett et al 1993). The recombinant
adenovirus used in this study is also replication deficient, noncyto-
lytic, and does not induce apparent phenotypic changes in infected
cells (Ranheim et al, 1993). Even in the rare case of the development
of a replication competent adenovirus, the cell would be lysed and
the vector cleared from the tissue. In addition, PCR analysis of
wounds demonstrated that PDGF-B transgene expression and
adenoviral transgene DNA are no longer detected in ischemic
wounds by 7 d. Further evidence for resolution of the induced
PDGF-B overexpression is the observation that the proliferative
changes in the base of the wound are limited and not progressive
as would be expected with continued PDGF-B overexpression. At
16 d the ischemic wounds treated with Ad-PDGF-B have a similar
appearance to non-ischemic wounds that were treated with vehicle,
with regard to cellularity, granulation tissue, and wound closure.
Adenoviral-mediated gene transfer of the human PDGF-B trans-
gene appears to be very effective in promoting PDGF-B overexpres-
sion resulting in reversal of the ischemia-induced wound healing
impairment in the rabbit ear excisional wound model. The efficiency
of gene transfer and biologic effects of adenoviral-mediated gene
transfer of PDGF-B are superior to previously reported applications
of exogenous PDGF-BB protein as well as other techniques of
gene transfer in wound healing. Adenoviral-mediated gene transfer
offers significant promise as a novel approach to efficient growth
factor delivery in impaired wound healing.
The authors gratefully acknowledge the assistance of Timothy Sablich and Bernard
Martin in the performance of these studies.
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